Bismuth Subnitrate
CAS 1304-85-4
Bismuth Subnitrate (CAS 1304-85-4) is a pharmaceutical compound with 0 bioactivity targets and 678 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Appendicolith | 31 | 149.515 | 10074458 |
| Blood phosphorus increased | 30 | 136.261 | 10050196 |
| Appendicitis | 31 | 118.52 | 10003011 |
| Ventricular fibrillation | 32 | 111.004 | 10047290 |
| Myasthenia gravis | 25 | 107.23 | 10028417 |
| Blood uric acid increased | 26 | 105.546 | 10005861 |
| Cardiogenic shock | 32 | 103.279 | 10007625 |
| Stress | 33 | 82.286 | 10042209 |
| Ascites | 32 | 81.106 | 10003445 |
| Multiple organ dysfunction syndrome | 33 | 72.042 | 10077361 |
| Abdominal distension | 33 | 69.738 | 10000060 |
| Dry mouth | 30 | 68.259 | 10013781 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Bismuth Subnitrate used for in pharmaceutical contexts?
Bismuth Subnitrate (CAS 1304-85-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Bismuth Subnitrate?
Bismuth Subnitrate has 678 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Appendicitis, Ventricular fibrillation, Myasthenia gravis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Bismuth Subnitrate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bismuth Subnitrate with EU status "permitted".
What clinical phase is Bismuth Subnitrate in?
No phase 1-4 clinical development badge is rendered for Bismuth Subnitrate because the matched compound identifier rows do not contain a max-phase value.